Dr. Reddy’s Board to Weigh Final FY 2025–26 Dividend on April 16 Disclosure
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dr Reddy’s Laboratories ( (RDY) ) just unveiled an update.
On April 16, 2026, Dr. Reddy’s Laboratories filed a Form 6-K with the U.S. Securities and Exchange Commission, providing an update to investors as a foreign private issuer under the Securities Exchange Act of 1934. The filing, signed by the company secretary, confirms ongoing compliance and disclosure practices for its overseas listings.
In a concurrent communication to Indian and international stock exchanges dated April 16, 2026, the company announced that its Board of Directors will meet to consider, among other items, a proposal to recommend a final dividend for the financial year 2025–26. The move signals potential shareholder returns for the year just ended and underscores the company’s attention to capital allocation and investor communication across its multiple trading venues.
The most recent analyst rating on (RDY) stock is a Buy with a $16.90 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Earnings-call takeaways are moderately positive due to pipeline progress and strong liquidity, but near-term margins and regulatory delays add risk. Technicals are neutral-to-soft and valuation is reasonable with a low dividend yield.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based global pharmaceutical company focused on generic medicines, active pharmaceutical ingredients and branded formulations across key markets including India and the U.S. The company is listed on the National Stock Exchange of India, BSE, the New York Stock Exchange and NSE IFSC, reflecting its diversified investor base and international market presence.
Average Trading Volume: 2,186,145
Technical Sentiment Signal: Sell
Current Market Cap: $10.89B
Learn more about RDY stock on TipRanks’ Stock Analysis page.
